Ask AI

Research Focus in Extrapulmonary Neuroendocrine Carcinomas: Emerging Insights on Targeting DLL3

Enhance your understanding of the role of DLL3 in extrapulmonary neuroendocrine carcinomas and emerging DLL3-targeted therapies to improve patient outcomes through a certified text module, podcast, expert-authored ClinicalThought commentary, and accompanying downloadable slides. 

Share

Program Content

Activities

Targeting DLL3 for EP NECs
Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: August 15, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.